Table 1.
Prevalence of autoantibodies in patients with SLE by Euroline ANA Profile (IgG).
Table 2.
Distribution of SLE patients with/without LN according to reactivity to anti-dsDNA, -nucleosome or -histone antibodies.
Fig 1.
The serum Levels of anti-dsDNA, -nucleosome and -histone antibodies in SLE patients.
(A) Serum levels of 3-pos and non 3-pos LN patients when they had active disease. (B) Serum levels of anti-dsDNA, -nucleosome, and -histone Abs in 3-pos SLE patients with/without LN. (C) Significantly higher titers of the three anti-nucleosome antibodies in 3-pos LN patients, compared to that in 2-pos or 1-pos cohorts. 3-pos: co-positivity of anti-dsDNA, -nucleosome, and -histone Abs; 2-pos: anti-dsDNA and -nucleosome, or anti-dsDNA and -histone, or anti -nucleosome and -histone; 1-pos: anti-dsDNA, or anti-nucleosome, or anti-histone. The antibody reactivity was determined by Euroline ANA profile (IgG).
Table 3.
Baseline laboratory characteristics between 3-pos and non 3-pos patients with LN.
Fig 2.
Correlation of 3-pos with LN subtype and kidney immune complex deposition in type IV LN.
(A) Correlations of 3-pos with LN subtype. (B) Deposition of immune complex in type IV LN in 3-pos or non-3-pos patients by immunohistochenistry. (C) Quantification of the postive staining in (B). IgG was labeled by HRP and represented for immune complex deposition. Four fields per biopsy sample were randomly counted and results were expressed as IOD/Area (Mean±SEM). Scale bar = 50 μm.
Fig 3.
Three-pos by Euroline ANA profile (IgG) was a marker for severe nephropathy in LN patients.
(A) Power of anti-dsDNA, -nucleosome and–histone Abs to differentiate active LN from inactive LN accessed by ROC curve. (B) Three-pos was the best marker for severe nephropathy. The relevant laboratory parameters on nephropathy includes increased Scr (≥ 133μmol/L), urinary protein (≥ 3.5g/24h) and urinary RBC (≥ 3/HP). 2A, 2B and 2C respectively indicated varied 2-pos by Euroline ANA profile (IgG) in LN patients; 2A: anti-dsDNA and -nucleosome; 2B: anti-dsDNA and -histone; 2C: anti-nucleosome and -histone.
Table 4.
Disease outcome in 3-pos and non 3-pos patients with LN.
Table 5.
Clinical treatments between 3-pos and non 3-pos patients with LN.
Fig 4.
Serum titres of anti-dsDNA, -nucleosome, and -histone Abs in 3-pos LN patients are significantly dropped when they underwent clinical recovery.
(A) Three-pos LN patients of clinical recovery had significantly decreased levels of SCr and BUN. (B) Serum levels of anti-dsDNA, -nucleosome and -histone antibodies in 3-pos LN patients before and after clinical treatment.